Table 3.

Difference in BMD (g/cm2) comparing intensive lifestyle (ILS) and metformin (MET) interventions to placebo at DPPOS year 12

	Unadjusted			Adjusteda
	Difference	95% CI	Pr > |t|	Difference	95% CI	Pr > |t|
Men
Total hip
ILS	−0.021	(−0.059, 0.016)	0.265	−0.005	(−0.039, 0.030)	0.796
MET	0.013	(−0.024, 0.050)	0.491	0.029	(−0.005, 0.062)	0.101
Placebo	ref			ref
Femoral neck
ILS	−0.021	(−0.063, 0.021)	0.321	−0.001	(−0.040, 0.037)	0.943
MET	0.017	(−0.023, 0.058)	0.402	0.036	(−0.001, 0.073)	0.058
Placebo	ref			ref
Lumbar spine
ILS	−0.024	(−0.076, 0.028)	0.365	−0.028	(−0.022, 0.078)	0.264
MET	0.017	(−0.034, 0.067)	0.521	0.020	(−0.028, 0.068)	0.411
Placebo	ref			ref
Women
Total hip
ILS	0.009	(−0.016, 0.033)	0.473	0.010	(−0.011, 0.031)	0.340
MET	0.006	(−0.018, 0.031)	0.623	0.012	(−0.009, 0.033)	0.258
Placebo	ref			ref
Femoral neck
ILS	0.014	(−0.014, 0.042)	0.329	0.010	(−0.014, 0.034)	0.419
MET	0.019	(−0.009, 0.047)	0.176	0.022	(−0.002, 0.046)	0.073
Placebo	ref			ref
Lumbar spine
ILS	−0.007	(−0.038, 0.025)	0.670	−0.006	(−0.034, 0.022)	0.683
MET	0.000	(−0.031, 0.032)	0.990	0.003	(−0.025, 0.031)	0.863
Placebo	ref			ref

^aAdjusted for age, race, baseline weight, baseline weight-bearing physical activity